Center for Innovative Care and Health Technology (ciTechcare), Instituto Politécnico, Leiria - R. de Santo André, Leiria, 2410, Portugal.
Instituto de Saúde Ambiental (ISAMB), Faculdade de Medicina, Universidade de Lisboa - Av, Lisboa, 1649-028, Portugal.
BMC Psychiatry. 2023 Apr 4;23(1):227. doi: 10.1186/s12888-023-04705-z.
Major Depressive Disorder (MDD) is a leading cause of disability worldwide. Approximately one-third of patients with MDD do not respond to treatment, and often exhibit elevated inflammation biomarkers, which are associated with worse prognosis. Previous research has linked healthier dietary patterns, such as the Mediterranean Diet (MedDiet), with a lower risk of MDD and symptoms of depression, potentially due to their anti-inflammatory properties. The aim of this study is to evaluate the effectiveness of a nutritional counselling intervention promoting MedDiet to alleviate symptoms of depression in adults recently diagnosed with MDD and presenting with elevated inflammation biomarkers.
This study is a randomized controlled trial (RCT) that will recruit adults from outpatient clinics, between the ages of 18 and 70 years who have been diagnosed with MDD and are currently receiving treatment with the first prescribed antidepressant, and who exhibit elevated inflammation biomarkers (interleukin-6 and/or C-reactive protein). The control group will receive treatment-as-usual (TAU) only. The primary outcome of the study will be the change in symptoms of depression, as measured by the Beck Depression Inventory 2 (BDI-II), after 12 weeks of intervention. Data analysis will follow an intention-to-treat approach. Secondary outcomes will include changes in inflammation biomarkers, quality of life, adherence to the MedDiet, and cost-effectiveness of nutritional counselling. All outcomes will be assessed at baseline, after the 12-week intervention, and at 6- and 12-months post-baseline.
This study will be the first RCT to evaluate the effect of a nutritional intervention with anti-inflammatory properties, as an adjuvant in the treatment of MDD, in individuals diagnosed with MDD and elevated inflammation biomarkers. The results of this study may contribute to the development of more effective and personalized interventions for MDD patients with elevated inflammation biomarkers.
重度抑郁症(MDD)是全球导致残疾的主要原因之一。大约三分之一的 MDD 患者对治疗没有反应,并且经常表现出升高的炎症生物标志物,这与更差的预后相关。先前的研究将更健康的饮食模式(如地中海饮食(MedDiet))与 MDD 和抑郁症状的风险降低联系起来,这可能是由于它们的抗炎特性。本研究旨在评估促进 MedDiet 的营养咨询干预措施对缓解最近被诊断为 MDD 且炎症标志物升高的成年人的抑郁症状的有效性。
这是一项随机对照试验(RCT),将招募来自门诊诊所的 18 至 70 岁之间的成年人,这些成年人被诊断为 MDD,目前正在接受首次开处方的抗抑郁药治疗,并且表现出升高的炎症标志物(白细胞介素-6 和/或 C 反应蛋白)。对照组将仅接受常规治疗(TAU)。研究的主要结果将是干预 12 周后,抑郁症状的变化,通过贝克抑郁量表 2(BDI-II)来衡量。数据分析将遵循意向治疗方法。次要结果将包括炎症标志物、生活质量、对 MedDiet 的依从性和营养咨询的成本效益的变化。所有结果将在基线、12 周干预后以及基线后 6 个月和 12 个月进行评估。
这将是第一项评估具有抗炎特性的营养干预作为辅助治疗 MDD 的 RCT,针对的是诊断为 MDD 且炎症标志物升高的个体。该研究的结果可能有助于为炎症标志物升高的 MDD 患者开发更有效和个性化的干预措施。